UNITED LAB (03933): Levofloxacin Eye Drops Approved for Market by China's NMPA

Stock News12-09

UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration (NMPA) for its Levofloxacin Eye Drops (specification: 0.488% (5ml: 24.4mg)), with the approval number H20256135.

Levofloxacin is a third-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV activity, thereby blocking bacterial DNA synthesis. It demonstrates significant antibacterial activity against a wide range of Gram-positive and Gram-negative bacteria.

The Levofloxacin Eye Drops feature broad-spectrum antibacterial properties and strong efficacy, making them widely applicable in clinical settings for treating conditions such as blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomianitis, keratitis, and perioperative ocular antisepsis. Currently, the product is listed as a Class A drug in China's National Reimbursement Drug List (2024 Edition).

This approval will further expand UNITED LAB's portfolio of ophthalmic products and strengthen its leading position in the field of ocular anti-infective treatments. The company remains committed to advancing new product development, providing comprehensive and high-quality pharmaceutical solutions for clinical use, and is expected to generate greater returns for the company and its shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102141054?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 17:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102141054","market":"hk","top_or_hot":-1,"title":"UNITED LAB (03933): Levofloxacin Eye Drops Approved for Market by China's NMPA","media":"Stock News","content":"<p>UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration (NMPA) for its Levofloxacin Eye Drops (specification: 0.488% (5ml: 24.4mg)), with the approval number H20256135.</p>\n<p>Levofloxacin is a third-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV activity, thereby blocking bacterial DNA synthesis. It demonstrates significant antibacterial activity against a wide range of Gram-positive and Gram-negative bacteria.</p>\n<p>The Levofloxacin Eye Drops feature broad-spectrum antibacterial properties and strong efficacy, making them widely applicable in clinical settings for treating conditions such as blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomianitis, keratitis, and perioperative ocular antisepsis. Currently, the product is listed as a Class A drug in China's National Reimbursement Drug List (2024 Edition).</p>\n<p>This approval will further expand UNITED LAB's portfolio of ophthalmic products and strengthen its leading position in the field of ocular anti-infective treatments. The company remains committed to advancing new product development, providing comprehensive and high-quality pharmaceutical solutions for clinical use, and is expected to generate greater returns for the company and its shareholders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITED LAB (03933): Levofloxacin Eye Drops Approved for Market by China's NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITED LAB (03933): Levofloxacin Eye Drops Approved for Market by China's NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-09 17:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration (NMPA) for its Levofloxacin Eye Drops (specification: 0.488% (5ml: 24.4mg)), with the approval number H20256135.</p>\n<p>Levofloxacin is a third-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV activity, thereby blocking bacterial DNA synthesis. It demonstrates significant antibacterial activity against a wide range of Gram-positive and Gram-negative bacteria.</p>\n<p>The Levofloxacin Eye Drops feature broad-spectrum antibacterial properties and strong efficacy, making them widely applicable in clinical settings for treating conditions such as blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomianitis, keratitis, and perioperative ocular antisepsis. Currently, the product is listed as a Class A drug in China's National Reimbursement Drug List (2024 Edition).</p>\n<p>This approval will further expand UNITED LAB's portfolio of ophthalmic products and strengthen its leading position in the field of ocular anti-infective treatments. The company remains committed to advancing new product development, providing comprehensive and high-quality pharmaceutical solutions for clinical use, and is expected to generate greater returns for the company and its shareholders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1102141054","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102141054","pubTimestamp":1765274302,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","03933":"联邦制药"},"translate_title":"联邦制药(03933)：左氧氟沙星滴眼液获中国NMPA批准上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"UNITED LAB (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has received approval from China's National Medical Products Administration (NMPA) for its Levofloxacin Eye Drops (specification: 0.488% (5ml: 24.4mg)), with the approval number H20256135.\nLevofloxacin is a third-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV activity, thereby blocking bacterial DNA synthesis. It demonstrates significant antibacterial activity against a wide range of Gram-positive and Gram-negative bacteria.\nThe Levofloxacin Eye Drops feature broad-spectrum antibacterial properties and strong efficacy, making them widely applicable in clinical settings for treating conditions such as blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomianitis, keratitis, and perioperative ocular antisepsis. Currently, the product is listed as a Class A drug in China's National Reimbursement Drug List (2024 Edition).\nThis approval will further expand UNITED LAB's portfolio of ophthalmic products and strengthen its leading position in the field of ocular anti-infective treatments. The company remains committed to advancing new product development, providing comprehensive and high-quality pharmaceutical solutions for clinical use, and is expected to generate greater returns for the company and its shareholders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102141054","isCrawlerRequest":true}